

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. McLaren Port Huron 2. 1221 Pine Grove Ave. Port Huron, MI 48061-3511		In accordance with letter dated September 13, 2021, 3. License No.: 21-20137-01 is amended in its entirety to read as follows:	4. Expiration Date: May 31, 2022 5. Docket No.: 030-18005 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Iodine-125 permitted by 10 CFR 35.400	7. Chemical and/or physical form A. Any B. Any C. Any D. Sealed Sources (Medi-Physics, Inc., Model 6702 and 6711 (OncoSeed); Theragenics Corporation, Model I-Seed AgX100)	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 1 curie total D. 600 millicuries total	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-20137-01

Docket or Reference No.:
030-18005

Amendment No. 30

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

9. Authorized use

E. Palladium-103 permitted by 10 CFR 35.400

E. Sealed Sources (Best Medical International, Inc., Model 2335; Theragenics Corporation, Model TheraSeed 200)

E. 600 millicuries total

E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-20137-01

Docket or Reference No.:
030-18005

Amendment No. 30

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 1221 Pine Grove Ave., Port Huron, Michigan, 48061.
11. The Radiation Safety Officer (RSO) for this license is David P. Tracy, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Hafeez Yusuf Ahmed, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

Neal Bhatt, M.D.

10 CFR 35.400

Jose A. Carrion, M.D.

10 CFR 35.100,10 CFR 35.200

John J. Ference, M.D.

10 CFR 35.100,10 CFR 35.200

Stephen D. Franklin, M.D.

10 CFR 35.400

Arthur J. Frazier, M.D.

10 CFR 35.300,10 CFR 35.400

Leopold M. Fregoli, M.D.

10 CFR 35.100,10 CFR 35.200

Matthew Johnson, M.D.

10 CFR 35.300 (limited to the parenteral administration of unsealed radioactive material requiring a written directive),10 CFR 35.400

Edward James Mauch, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Daniel K. Shogren, D.O.

10 CFR 35.100,10 CFR 35.200

David P. Tracy, M.D.

10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 21-20137-01

Docket or Reference No.:
030-18005

Amendment No. 30

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated November 11, 2011 (ML113210733)
- B. Letter dated October 1, 2014 (ML14294A799)
- C. Letter dated August 29, 2016 (ML16244A543)
- D. Letter dated September 9, 2016 (ML16256A523)
- E. Letter dated September 19, 2016 (ML16263A238)
- F. Letter dated October 7, 2016 (ML16281A460)



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-20137-01

Docket or Reference No.:
030-18005

Amendment No. 30

- G. Letter dated March 17, 2020 (ML20077M413)
H. Letter dated August 28, 2020 (ML20253A320)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: November 23, 2021

By: _____

Magdalena R. Gryglak
Region 3